Nephrocare Health Services Limited has uploaded the transcript of its investors' conference call regarding the first quarter of FY27 financial results. The session took place on August 12, 2026, and addressed the unaudited standalone and consolidated performance for the period ended June 30, 2026.

The disclosure was made in compliance with Regulation 30, Regulation 46(2), and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Call Details

The transcript is accessible via the company's official website at www.nephroplus.com . This release serves as a continuation of the earlier communication dated July 24, 2026, and August 12, 2026, which contained the written financial statements and notice regarding the discussion.

Kishore Kathri, Company Secretary and Head Legal at Nephrocare, signed the disclosure letter. The document confirms that the recording and transcript are available for public record, ensuring transparency for investors and analysts reviewing the quarterly performance.

Nephrocare Health Services has expanded its presence in the Philippines with the acquisition of dialysis center assets from Assumption Dialysis Center. The company’s overseas step-down wholly-owned subsidiary, Nephrocare Health Care Services Philippines Inc., entered into an Asset Transfer Agreement dated August 14, 2026, which was executed on August 17, 2026.

The total consideration for the transaction is PhP 75,000,000 (Philippine Pesos Seventy-Five Million Only). The acquired assets pertain to a dialysis center located at Daang Maharlika, Brgy. Bunga, Abuyog, Leyte, Philippines.

Transaction Details

This acquisition follows an earlier deal by Nephrocare Health Services to acquire assets of Juan Nephro Dialysis Center in Davao City for PhP 71.8 million, under an agreement dated August 12, 2026. The new deal with Assumption Dialysis Center is structured as an asset purchase rather than a share acquisition.

According to the disclosure made to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, there are no special rights attached to the agreement, such as director appointments or subscription rights. The seller is not related to the promoter group or group companies of Nephrocare Health Services, meaning the transaction does not fall within the scope of related-party transactions and was executed at arm’s length.

Regulatory Disclosure

Nephrocare Health Services Limited issued the disclosure pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that no shares were issued as part of this agreement, and no loan facilities were involved in the transaction structure.